Editorial: Therapeutic targeting of splicing variants in cancer

Frontiers in Pharmacology

Pharmacology

Verónica Vallejo-Ruiz¹  Stephanie Dobersch²  Pouya Sarvari³  Karla Rubio⁴  Aglaia Ntokou⁵ 

[1] Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla, Mexico;Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, United States;Independent Researcher, Puebla, Mexico;International Laboratory EPIGEN, Consejo de Ciencia y Tecnología del Estado de Puebla (CONCYTEP), Instituto de Ciencias, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Mexico;Laboratoire IMoPA, Université de Lorraine, CNRS, UMR 7365, Nancy, France;Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, New Haven, CT, United States;Yale Department of Genetics, New Haven, CT, United States;

关键词: alternative splicing;    spliceosome;    splicing factors;    aberrant splicing;    pre-mRNA;   

DOI  :  10.3389/fphar.2023.1206342

 received in 2023-04-15, accepted in 2023-04-20,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Sarvari, Rubio, Dobersch, Ntokou and Vallejo-Ruiz.